Think of the cells that drive aging as a few bad actors in a big crowd. Insilico Medicine wants to find them early and have the body’s own immune cells walk them out. The company, listed in Hong Kong (HKEX: 3696), has announced a research program called Longevity Vaccines to try.
Here’s what it means in practice. The aim is a single dose, not a lifelong course, that clears the first culprit cells behind age-related disease and then switches itself off.
Which cells, and how
Insilico says many diseases of aging start with small, identifiable groups of cells that carry known surface markers. It names three: senescent cells that release inflammatory proteins (the senescence-associated secretory phenotype, or SASP), activated fibroblasts that drive fibrosis, and autoreactive lymphocytes that stop the body tolerating itself. The plan is to remove them within a preventive window, rather than treat the damage they cause later. The company points to peer-reviewed work showing that engineered T cells can clear such cells, with lasting benefit from one course.
The delivery system is a short-lived genetic instruction written in circular mRNA and packed into a targeted lipid nanoparticle. Inside the body it arms a patient’s own T cells to recognize and remove the chosen targets. Circular mRNA resists breakdown, so the instruction lasts long enough to work yet still fades, and the targeted nanoparticle is meant to deliver it only where it should go. Neuroscience News, which covered the announcement, noted that this avoids permanent genetic changes and the lab engineering that ex vivo CAR T therapies need.
Picking the target
For preventive medicine the bar is high. A target has to show up at the earliest stage of disease and leave a wide safety margin. Insilico runs candidates through its Pharma.AI platform, which includes PandaOmics for multi-omics target discovery, Chemistry42 for designing ionizable lipids and delivery systems, generative tools for designing binders, and inClinico for trial design. Antigens are ranked on evidence, timing of expression, how specific they are against a whole-body surface atlas, and whether they can be delivered. Automated labs then test the candidates, and the results feed back into the rankings. The company’s aging models and its Virtual Aging Cell help locate the point where cells first drift from health.
The first target is the aging immune system: senescent lymphocytes that pile up and bring weaker vaccine responses and a higher risk of infection and cancer. Metabolic dysfunction and membranous nephropathy are among the other indications under evaluation. “We built Insilico to treat aging and disease together, and to prove that AI can design medicines that deliver real patient impact,” said co-CEO and founder Alex Zhavoronkov. He called the new program an extension of that rigor to “programmable, single-dose therapies that clear the root-cause cells of age-related disease, starting with the immune system itself.”
The record behind it
The program leans on Rentosertib (ISM001-055), a TNIK inhibitor whose target and molecule were both AI-designed. It went from target to preclinical candidate in 18 months, restored lung capacity in a randomized Phase IIa trial for idiopathic pulmonary fibrosis, and has entered Phase III.
The money side is notable too. Insilico reported first-half 2026 revenue of about $106 million, up 287 percent, and its first profitable half-year since listing, with adjusted net profit above $51 million. Partners include Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS and Tenacia. Contract value for deals announced in 2026 has reached roughly $7.3 billion, and about $11 billion for its major collaborations since 2021.
By late August the company had also nominated nine development candidates in eight months, a record for a year.
Sources
- Insilico Launches AI-driven Longevity Vaccines Research for Aging-related Diseases and Human Longevity
- AI-Designed “Longevity Vaccines” Target the Earliest Culprits of Cellular Aging – Neuroscience News
